Filing Flows › Standard Biotools (LAB) › Q3 2026 › vs Q3 2025
Standard Biotools (LAB) Q3 2026 vs Q3 2025 (year over year)
Standard Biotools's revenue fell $167K (-0.9%) from $19.6M in Q3 2025 to $19.4M in Q3 2026. The biggest changes: Services and Other Revenue −$695K (-12%); Product +$528K (+4%).
Standard Biotools, Q3 2026: revenue $19.4M (-0.9% year over year), operating margin -102.0%, net earnings $13.5M, operating cash flow −$6.2M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Consumables | $8.3M | $8.7M | −$375K | -4% |
| Instruments | $6.0M | $5.1M | $903K | +18% |
| Product | $14.3M | $13.8M | $528K | +4% |
| Services and Other Revenue | $5.1M | $5.8M | −$695K | -12% |
| Revenue | $19.4M | $19.6M | −$167K | -0.9% |
| Other income, net | $33.3M | −$3.0M | $36.2M | — |
| Costs & expenses | $52.7M | $55.5M | −$2.8M | -5% |
| Operating costs | $39.2M | $52.5M | −$13.3M | -25% |
| Income tax | $27K | −$1.2M | $1.2M | — |
| Net earnings | $13.5M | −$34.7M | $48.2M | — |
| Cost of revenue | $8.6M | $10.1M | −$1.5M | -15% |
| Research & development | $2.1M | $6.4M | −$4.3M | -67% |
| SG&A | $16.8M | $26.6M | −$9.8M | -37% |
| Other operating costs | $11.7M | $9.5M | $2.2M | +23% |
| Operating cash sources | $24.6M | −$2.5M | $27.1M | — |
| Depreciation & amortization | $1.2M | $1.5M | −$318K | -21% |
| Share-based compensation | $3.7M | $8.5M | −$4.8M | -56% |
| Cash used in operations | $6.2M | $22.2M | −$16.0M | -72% |
| Working capital & other | $24.6M | −$2.5M | $27.1M | — |
Questions
How much did Standard Biotools's revenue grow year over year in Q3 2026?
Standard Biotools's revenue fell $167K (-0.9%) from $19.6M in Q3 2025 to $19.4M in Q3 2026.
What drove Standard Biotools's revenue change in Q3 2026?
Services and Other Revenue −$695K (-12%); Product +$528K (+4%).